Key result
ELECTRA-SIRIO 2 trial design evaluates low-dose ticagrelor with or without ASA in ACS patients.
Why the study?
Does low-dose ticagrelor with or without acetylsalicylic acid improve outcomes in patients with acute coronary syndrome?
Does low-dose ticagrelor with or without acetylsalicylic acid improve outcomes in patients with acute coronary syndrome?
Answers are grounded in this paper and cite their sources.
This paper describes the rationale and design of the ELECTRA-SIRIO 2 trial evaluating low-dose ticagrelor with or without acetylsalicylic acid in patients with acute coronary syndrome.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
A 2021 study studied this question. Low-dose ticagrelor with or without acetylsalicylic acid will be evaluated in patients with acute coronary syndrome according to the rationale and design of the ELECTRA-SIRIO 2 trial.
Synapse has enriched 10 related papers. Consider them for comparative context: